Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy

Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which pr...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2021-11, Vol.11 (11), p.1187
Main Authors: Roacho-Pérez, Jorge A., Garza-Treviño, Elsa N., Delgado-Gonzalez, Paulina, G-Buentello, Zuca, Delgado-Gallegos, Juan Luis, Chapa-Gonzalez, Christian, Sánchez-Domínguez, Margarita, Sánchez-Domínguez, Celia N., Islas, Jose Francisco
Format: Article
Language:English
Subjects:
Antibodies
Aptamers
Biodegradable materials
Cancer
Cancer therapies
Carbon nanotubes
Chemotherapy
Cisplatin
Diabetes
Drug delivery
Drugs
Enzymes
Gemcitabine
Gene therapy
Glucagon
Hyperthermia
Irinotecan
Lethality
Lipids
Medical prognosis
Medical research
Micelles
molecular markers
Mortality
nanomedicine
Nanoparticles
Nanotechnology
Nanotubes
Oxaliplatin
Paclitaxel
Pancreatic cancer
Proteins
Review
Side effects
target therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which produce several side effects. This review focuses on the use of targeted nanoparticles, such as metallic nanoparticles, polymeric nanoparticles, liposomes, micelles, and carbon nanotubes as an alternative to standard treatment for pancreatic cancer. The principal objective of nanoparticles is reduction of the side effects that conventional treatments produce, mostly because of their non-specificity. Several molecular markers of pancreatic cancer cells have been studied to target nanoparticles and improve current treatment. Therefore, properly functionalized nanoparticles with specific aptamers or antibodies can be used to recognize pancreatic cancer cells. Once cancer is recognized, these nanoparticles can attack the tumor by drug delivery, gene therapy, or hyperthermia.
ISSN:2075-1729
2075-1729
DOI:10.3390/life11111187